TheraRadar
← Back
Data updated: Jun 28, 2026

RANBAXY LABS LTD

Generics

RANBAXY LABS LTD is a generic drug manufacturer focused on Infectious Disease, Gastroenterology, Dermatology.

1964
Since
41
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

RANBAXY LABS LTD's Key Drugs

RANBAXY LABS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

RANBAXY LABS LTD's Recent FDA Approvals

New NDA/BLA approvals for RANBAXY LABS LTD over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

RANBAXY LABS LTD's Therapeutic Areas

RANBAXY LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 36%
4 drugs
Gastroenterology 18%
2 drugs
Dermatology 18%
2 drugs
Immunology 18%
2 drugs
Respiratory 9%
1 drugs

RANBAXY LABS LTD Pipeline Snapshot

Active clinical trials for RANBAXY LABS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling